A New Clonal Chromosomal Aberration (47, XY, +21) in Atrial Myxoma from an Elderly Male Patient

Stępień, Ewa; Grudzień, Grzegorz; Andres, Marek; Jakóbczyk, Małgorzata; Czapczak, Dorota; Kapusta, Przemysław; Frasik, W; Myrdko, Tomasz; Sadowski, Jerzy

doi:10.4081/cardiogenetics.2012.e3

Cited by 3 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 32 ] . In addition, this patient had significantly decreased troponin I values on PODs 7 and 13, much lower than those of the patient reported by Stępień's et al [ 26 ] . This could be interpreted by the associated coronary artery disease in the latter patient [ 26 ] .…”

Section: Discussioncontrasting

confidence: 70%

“…Troponin I levels of alive patients was 2.01 (range, 1.01-3.65) and 4.26 (range, 2.18-8.37) µg/L at POH 2 and on POD 1, while those of the deceased were 3.63 (range, 1.62-8.26) and 11.85 (range, 5.59-23.96) µg/L, respectively [ 14 ] . In a patient with a cardiac myxoma and associated coronary artery stenosis, his troponin I was 3.56 µg/L on POD 13 [ 26 ] . The present patient with old cerebral infarct had an uneventful recovery after the resection of cardiac myxoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic prediction of troponins in cardiac myxoma: case study with literature review

Yuan

2014

Revista Brasileira De Cirurgia Cardiovascular

View full text Add to dashboard Cite

ObjectiveIt was supposed that troponins in cardiac myxoma patients might be in a same fashion as in the conditions without myocardial injury. In order to verify this hypothesis, troponins in cardiac myxoma patients were discussed by presenting a comprehensive retrieval of the literature with incorporating the information of a recent patient.MethodsPostoperative detections of troponin I, creatine kinase isoenzyme MB (CK-MB) and N-terminal pro-B-type natriuretic peptide revealed elevated troponin I and CK-MB and normal N-terminal pro-B-type natriuretic peptide. Postoperative troponin I and CK-MB shared a same trend, reaching a peak value at postoperative hour 2, gradually decreased on postoperative day 1, and reached a plateau on postoperative days 7 and 13. A significant correlation could be noted between the postoperative values of the two indicators (Y=0.0714X + 0.6425, r2=0.9111, r=0.9545, P=0.0116). No significant linear correlation between troponin I and N-terminal pro-B-type natriuretic peptide were found. Literature review of troponins in cardiac myxoma patients revealed the uncomplicated patients had a normal or only slightly elevated troponin before open heart surgery. However, the complicated patients (with cerebral or cardiac events) showed a normal preoperative troponin in 3 (23.1%) and an elevated troponin in 10 (76.9%) patients (χ2=7.54, P=0.0169, Fisher's exact test). The overall quantitative result of troponin I was 2.45±2.53 µg/L, and that of troponin T was 3.10±4.29 mg/L, respectively.ConclusionTroponins are not necessarily elevated in patients with a cardiac myxoma without coronary syndrome. By contrast, patients with a cardiac myxoma with an elevated troponin may herald the presence of an associated coronary event. An old cerebral infarct does not necessarily cause an elevation of troponin or B-type natriuretic peptide, or new neurological events, but might lead to a delayed awakening.

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Prognostic prediction of troponins in cardiac myxoma: case study with literature review

Yuan

2014

Revista Brasileira De Cirurgia Cardiovascular

View full text Add to dashboard Cite

show abstract

“…The first description of five left ancient ventricular polypus specimens was summarized by T. W. King in 1845 [22]. CM is the most common cardiac tumor in adults and accounts for approximately 50-75% and > 50% of benign and primary cardiac neoplasms, respectively [23][24][25][26][27][28]. Left atrial CM is twice most common in women, compared to men [29].…”

Section: Introductionmentioning

confidence: 99%

Developing a novel positronium biomarker for cardiac myxoma imaging

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose Cardiac myxoma (CM), the most common cardiac tumor in adults, accounts for 50–75% of benign cardiac tumors. The diagnosis of CM is often elusive, especially in young stroke survivors and transthoracic echocardiography (TTE) is the initial technique for the differential diagnostics of CM. Less invasive cardiac computed tomography (CT) and magnetic resonance imaging (MRI) are not available for the majority of cardiac patients. Here, a robust imaging approach, ortho-Positronium (o-Ps) imaging, is presented to determine cardiac myxoma extracted from patients undergoing urgent cardiac surgery due to unexpected atrial masses. We aimed to assess if the o-Ps atom, produced copiously in intramolecular voids during the PET imaging, serves as a biomarker for CM diagnosing. Methods Six perioperative CM and normal (adipose) tissue samples from patients, with primary diagnosis confirmed by the histopathology examination, were examined using positron annihilation lifetime spectroscopy (PALS) and micro-CT. Additionally, cell cultures and confocal microscopy techniques were used to picture cell morphology and origin. Results We observed significant shortening in the mean o-Ps lifetime in tumor with compare to normal tissues: an average value of 1.92(02) ns and 2.72(05) ns for CM and the adipose tissue, respectively. Microscopic differences between tumor samples, confirmed in histopathology examination and micro-CT, did not influenced the major positronium imaging results. Conclusions Our findings, combined with o-Ps lifetime analysis, revealed the novel emerging positronium imaging marker (o-PS) for cardiovascular imaging. This method opens the new perspective to facilitate the quantitative in vivo assessment of intracardiac masses on a molecular (nanoscale) level.

show abstract

“…The first description of five left ancient ventricular polypus specimens was summarized by T. W. King in 1845 (20). CM is the most common cardiac tumor in adults and accounts for approximately 50-75% and >50% of benign and primary cardiac neoplasms, respectively (21)(22)(23)(24)(25)(26). Left CM is twice most common in women, compared to men (27).…”

mentioning

confidence: 99%

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

Moskal

Kubicz

Grudzień

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Here, positronium imaging is presented to determine cardiac myxoma (CM) extracted from patients undergoing urgent cardiac surgery due to unexpected atrial masses. Positronium is an atom build from an electron and a positron, produced copiously in intra-molecular voids during the PET imaging. CM, the most common cardiac tumor in adults, accounts for 50-75% of benign cardiac tumors. We aimed to assess if positronium serves as a biomarker for diagnosing CM. Perioperative examinations and histopathology staining in six patients confirmed the primary diagnosis of CM. We observed significant differences in the mean positronium lifetime between tumor and normal tissues, with an average value of 1.92(02) ns and 2.72(05) ns for CM and the adipose tissue, respectively. Our findings, combined with positronium lifetime imaging, reveals the novel emerging positronium biomarker for cardiovascular imaging.One-Sentence SummaryPositronium may serve as an imaging biomarker for cancer diagnostics.

show abstract

A New Clonal Chromosomal Aberration (47, XY, +21) in Atrial Myxoma from an Elderly Male Patient

Cited by 3 publications

References 20 publications

Prognostic prediction of troponins in cardiac myxoma: case study with literature review

Prognostic prediction of troponins in cardiac myxoma: case study with literature review

Developing a novel positronium biomarker for cardiac myxoma imaging

Developing a Novel Positronium Biomarker for Cardiac Myxoma Imaging

Contact Info

Product

Resources

About